Abstract:Metformin (MET) is the preferred first-line treatment for patients with type 2 diabetes. However, the mechanism of diabetic peripheral neuropathy (DPN) is still unclear. To improve the oral utilization of metformin, a metformin nanoemulsion (MET-NE) was prepared to investigate its effects on DPN and its underlying mechanism. In this study, a DPN model was established in Wistar rats induced by streptozotocin (STZ). The diabetic rats were randomly divided into four groups: the diabetic model group (DM group), the metformin tablet-treated group (MET group), the metformin nanoemulsion-treated group (MET-NE group), and a normal control group consisting of five normal Wistar rats. All groups were administered the treatment orally for a period of 10 weeks. The findings of the study demonstrated that both MET and MET-NE significantly reduced blood glucose levels, glycated serum protein levels, food intake, and water intake in DM rats. It was also observed that MET-NE was more effective than MET in reducing blood glucose levels. Additionally, both MET and MET-NE treatments significantly increased the motor nerve conduction velocity (MNCV), sensory nerve conduction velocity (SNCV), and sensory nerve action potential (SNAP) amplitude in DM rats. Furthermore, these treatments improved mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL), resulting in a reduced sensitivity to pain stimuli. Moreover, both MET and MET-NE treatments promoted the phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC) proteins, as well as increased the activity of autophagic proteins in the sciatic nerve. However, no significant differences were observed between MET and MET-NE treatments in terms of these effects. In conclusion, the MET-NE demonstrated a rapid decrease in blood glucose levels and improved glucose tolerance and metabolism, which was found to be superior to MET. Furthermore, MET-NE significantly improved the neurophysiological function and sciatic nerve pain threshold in DPN rats. These beneficial effects may be attributed to the regulation of AMPK-mediated autophagy by MET-NE.

Metformin attenuates diabetic neuropathic pain via AMPK/NF-κB signaling pathway in dorsal root ganglion of diabetic rats

Metformin Alleviates Pain States by Regulating the Balance of Spinal Synaptic Transmission

Effect of Metformin Nanoemulsion Through AMP-activated Protein Kinase (Ampk)-Mediated Autophagy on Diabetic Neuropathy

Metformin Attenuates Bone Cancer Pain by Reducing TRPV1 and ASIC3 Expression

Metformin Relieves Bortezomib-Induced Neuropathic Pain by Regulating AMPKa2-Mediated Autophagy in the Spinal Dorsal Horn

Metformin relieves bone cancer pain by reducing TGFβRI-TRPV1 signaling in rats

Obesity Increases Neuropathic Pain Via the AMPK-ERK-NOX4 Pathway in Rats

Metformin Relieves Bone Cancer Pain by Reducing TGF(3RI-TRPV1 Signaling in Rats

Inhibition of phosphorylated calcium/calmodulin-dependent protein kinase IIα relieves streptozotocin-induced diabetic neuropathic pain through regulation of P2X3 receptor in dorsal root ganglia

Role of P2X4 Receptor in Spinal Cord in Diabetic Neuropathic Pain in Rats

Ammoxetine attenuates diabetic neuropathic pain through inhibiting microglial activation and neuroinflammation in the spinal cord

Downregulation of Glucose-6-phosphate Dehydrogenase Contributes to Diabetic Neuropathic Pain Through Upregulation of Toll-Like Receptor 4 in Rats

Quercetin Relieved Diabetic Neuropathic Pain by Inhibiting Upregulated P2X4 Receptor in Dorsal Root Ganglia

Effects of Subcutaneous Transfection of Human Beta-Nerve Growth Factor Gene on Expression of Substance P in Dorsal Root Ganglion in a Rat Model of Diabetic Neuropathic Pain

Osthole Alleviated Diabetic Neuropathic Pain Mediated by the P2X4 Receptor in Dorsal Root Ganglia.

Glucagon-like peptide-1 receptor agonist attenuates diabetic neuropathic pain via inhibition of NOD-like receptor protein 3 inflammasome in brain microglia

AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice

Effects of DHA on neuropathic pain and JNK/CXCL1 signaling pathway in diabetic rats

Metformin alleviates renal injury in diabetic rats by inducing Sirt1/FoxO1 autophagic signal axis

Metformin alleviates renal injury in diabetic rats by inducing Sirt1/FoxO1 autophagic signal axis.

Mechanisms Underlying Purinergic P2X3 Receptor-Mediated Mechanical Allodynia Induced in Diabetic Rats